# TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

> **NCT00683631** · — · COMPLETED · sponsor: **University of Louisville** · enrollment: 183 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** TheraSphere HUD

## Key facts

- **NCT ID:** NCT00683631
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2023-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683631, "TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00683631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*